The Latest Breaking News from Novo

Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.

An age-old battle in pharmaceuticals could further rattle Eli Lilly stock and its potential $100 billion market in weight-loss drugs.

A shocking study in The Lancet showed that nearly three-quarters of U.S. adults are overweight or obese. Chances are that by 2050, there will be 260 million overweight Americans. We already have GLP-1 drugs, and amylin-based drugs are next. Novo Nordisk's compound, Cagrilintide, will be combined with semaglutide in its…

Novo Nordisk stock fell Wednesday after the drugmaker's weight-loss drug beat forecasts, but Ozempic sales missed.

Novo Nordisk faces a challenge turning around the fortunes of residents in a major Danish manufacturing hub.

Viking Therapeutics reported strong weight loss for higher doses of its experimental obesity drug.

Novo Nordisk has lost about a quarter of its value since the end of June. Meanwhile, indications are that its diabetes and weight-loss drugs may be useful in fighting cardiovascular disease, arthritis, opioid and alcohol addiction, and Alzheimer's. Novo remains a leader in the sector, and is trading at a…

Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment.

Viking Therapeutics stock is on the rise as the battle to develop new weight-loss drugs heats up. Here's what's at stake for the pharma giants fighting for position.